Skip to main content
. 2020 Apr 9;21(6):e49783. doi: 10.15252/embr.201949783

Figure EV1. (Related to Fig 1). LAQ partially alleviated phenotypes in PLP‐150Q mice.

Figure EV1

  1. Schematic of study design. PLP‐150Q mice and the control PLP‐23Q mice at the age of 3 months were orally administrated with LAQ (5 or 25 mg/kg/day as indicated in figure) for 2 months. The brain tissues were collected for pathological examination after behavioral studies.
  2. Rotarod performance and balance beam tests showed severe motor impairment in PLP‐150Q mice. Administrating 5 or 25 mg/kg LAQ could alleviate the impairment. One‐way ANOVA followed with Tukey's test. **P = 0.00735; *P = 0.04086; n = 12 mice per group for rotarod perform test and n = 6 mice per group for balance beam test. Data are presented as mean ± SEM.
  3. The PLP‐150Q mice show reduced body weight and early death, which were not altered by the treatment with 5 or 25 mg/kg LAQ for 2 months. n = 12 mice each group, which were treated with LAQ at 3 months of age. Data are mean ± SEM.
  4. PLP‐150Q/GFP mice show GFP labeling of oligodendrocyte processes, which are reduced in the corpus callosum when compared with PLP‐23Q/GFP mice and were increased after 5 mg/kg LAQ treatment for 2 months. Quantitative analysis of the number of GFP‐positive oligodendrocytes and process length was shown under the micrographs. n = 3 mice in each group. Process length was presented in a.u. One‐way ANOVA followed with Tukey's test. ***P = 3.92 × 10−5; **P = 0.00187. Data were mean ± SEM. Scale bar: 40 μm.